Shares of Outlook Therapeutics edged up 1.8% in pre-market to $1.73, extending a rally that has seen the stock roughly triple from its March lows. The catalyst: the FDA accepted the company's resubmitted application for its wet age-related macular degeneration drug, setting a decision deadline of July 29, 2026 . With no new filings this morning, today's move is positioning ahead of that binary verdict — one that will determine the fate of a company valued at roughly $235 million whose trailing revenue is just $1.4 million against a net loss of $62.4 million .
A Won Appeal Puts the Drug on the Doorstep of Approval. The FDA's Office of New Drugs concluded that substantial evidence of effectiveness has been established for the drug in treating wet AMD , overturning a December 2025 rejection. The agency classified the resubmission as a Class 1 review — a 60-day turnaround focused on labeling, not new clinical data . That shorter timeline suggests the science is settled and the remaining work is administrative, which meaningfully raises the probability of a green light.
The U.S. Prize Is Enormous — and Untapped. Off-label compounded bevacizumab dominates U.S. wet AMD care, with roughly 2.7 million injections annually . If approved, Outlook's drug would become the first and only FDA-approved ophthalmic formulation of bevacizumab for wet AMD , giving it standardized manufacturing and an official label that compounded alternatives lack. Bevacizumab currently costs between $17 and $50 per injection , far below branded competitors priced above $1,400 — a cost advantage that could drive rapid adoption if distribution and reimbursement are executed well.
The Cash Situation Is Precarious. As of March 31, Outlook had just $7.7 million in cash, was burning $14.1 million per quarter, and recently priced a $5 million stock offering while cutting warrant exercise prices . The company also took on an $18.4 million note from Atlas Sciences at an original issue discount, carrying interest of prime plus 3% . Even with approval, a full U.S. launch will require additional capital — likely meaning more dilution for existing shareholders.
Short Sellers Are Piling In Ahead of the Verdict. Short interest stands at 16.1 million shares, up 77.5% from the prior period, representing 16.7% of shares . That heavy bet against the stock creates two-way risk: approval could trigger a violent squeeze, while another rejection would validate the bears and crater a company running on fumes. Outlook's valuation is almost entirely tied to one U.S. regulatory outcome — July 29 will either vindicate the rally or end it.